Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury.
Acute liver disease
Inflammation
Nanobody
Pannexin1
Therapy
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
11 Oct 2023
11 Oct 2023
Historique:
received:
26
05
2023
accepted:
29
09
2023
medline:
1
11
2023
pubmed:
12
10
2023
entrez:
11
10
2023
Statut:
epublish
Résumé
The opening of pannexin1 channels is considered as a key event in inflammation. Pannexin1 channel-mediated release of adenosine triphosphate triggers inflammasome signaling and activation of immune cells. By doing so, pannexin1 channels play an important role in several inflammatory diseases. Although pannexin1 channel inhibition could represent a novel clinical strategy for treatment of inflammatory disorders, therapeutic pannexin1 channel targeting is impeded by the lack of specific, potent and/or in vivo-applicable inhibitors. The goal of this study is to generate nanobody-based inhibitors of pannexin1 channels. Pannexin1-targeting nanobodies were developed as potential new pannexin1 channel inhibitors. We identified 3 cross-reactive nanobodies that showed affinity for both murine and human pannexin1 proteins. Flow cytometry experiments revealed binding capacities in the nanomolar range. Moreover, the pannexin1-targeting nanobodies were found to block pannexin1 channel-mediated release of adenosine triphosphate. The pannexin1-targeting nanobodies were also demonstrated to display anti-inflammatory effects in vitro through reduction of interleukin 1 beta amounts. This anti-inflammatory outcome was reproduced in vivo using a human-relevant mouse model of acute liver disease relying on acetaminophen overdosing. More specifically, the pannexin1-targeting nanobodies lowered serum levels of inflammatory cytokines and diminished liver damage. These effects were linked with alteration of the expression of several NLRP3 inflammasome components. This study introduced for the first time specific, potent and in vivo-applicable nanobody-based inhibitors of pannexin1 channels. As demonstrated for the case of liver disease, the pannexin1-targeting nanobodies hold great promise as anti-inflammatory agents, yet this should be further tested for extrahepatic inflammatory disorders. Moreover, the pannexin1-targeting nanobodies represent novel tools for fundamental research regarding the role of pannexin1 channels in pathological and physiological processes.
Sections du résumé
BACKGROUND
BACKGROUND
The opening of pannexin1 channels is considered as a key event in inflammation. Pannexin1 channel-mediated release of adenosine triphosphate triggers inflammasome signaling and activation of immune cells. By doing so, pannexin1 channels play an important role in several inflammatory diseases. Although pannexin1 channel inhibition could represent a novel clinical strategy for treatment of inflammatory disorders, therapeutic pannexin1 channel targeting is impeded by the lack of specific, potent and/or in vivo-applicable inhibitors. The goal of this study is to generate nanobody-based inhibitors of pannexin1 channels.
RESULTS
RESULTS
Pannexin1-targeting nanobodies were developed as potential new pannexin1 channel inhibitors. We identified 3 cross-reactive nanobodies that showed affinity for both murine and human pannexin1 proteins. Flow cytometry experiments revealed binding capacities in the nanomolar range. Moreover, the pannexin1-targeting nanobodies were found to block pannexin1 channel-mediated release of adenosine triphosphate. The pannexin1-targeting nanobodies were also demonstrated to display anti-inflammatory effects in vitro through reduction of interleukin 1 beta amounts. This anti-inflammatory outcome was reproduced in vivo using a human-relevant mouse model of acute liver disease relying on acetaminophen overdosing. More specifically, the pannexin1-targeting nanobodies lowered serum levels of inflammatory cytokines and diminished liver damage. These effects were linked with alteration of the expression of several NLRP3 inflammasome components.
CONCLUSIONS
CONCLUSIONS
This study introduced for the first time specific, potent and in vivo-applicable nanobody-based inhibitors of pannexin1 channels. As demonstrated for the case of liver disease, the pannexin1-targeting nanobodies hold great promise as anti-inflammatory agents, yet this should be further tested for extrahepatic inflammatory disorders. Moreover, the pannexin1-targeting nanobodies represent novel tools for fundamental research regarding the role of pannexin1 channels in pathological and physiological processes.
Identifiants
pubmed: 37821897
doi: 10.1186/s12951-023-02137-1
pii: 10.1186/s12951-023-02137-1
pmc: PMC10566086
doi:
Substances chimiques
Adenosine Triphosphate
8L70Q75FXE
Anti-Inflammatory Agents
0
Inflammasomes
0
Single-Domain Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
371Subventions
Organisme : European Research Council
ID : Proof-of-Concept grant 861913
Pays : International
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Björnsson ES. Global epidemiology of drug-induced liver injury (DILI). Curr Hepatol Reports. 2019;18:274–9.
doi: 10.1007/s11901-019-00475-z
Jayaraman T, Lee YY, Chan WK, Mahadeva S. Epidemiological differences of common liver conditions between Asia and the West. JGH Open. 2020;4:332–9.
pubmed: 32514433
doi: 10.1002/jgh3.12275
Pievsky D, Rustgi N, Pyrsopoulos NT. Classification and epidemiologic aspects of acute liver failure. Clin Liver Dis. 2018;22:229–41.
pubmed: 29605063
doi: 10.1016/j.cld.2018.01.001
Stravitz RT, Lee WM. Acute liver failure. Lancet. 2019;394:869–81.
pubmed: 31498101
doi: 10.1016/S0140-6736(19)31894-X
Jaeschke H, Akakpo JY, Umbaugh DS, Ramachandran A. Novel therapeutic approaches against acetaminophen-induced liver injury and acute liver failure. Toxicol Sci. 2020;174:159–67.
pubmed: 31926003
pmcid: 7098369
doi: 10.1093/toxsci/kfaa002
Antoniades CG, Quaglia A, Taams LS, Mitry RR, Hussain M, Abeles R, et al. Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans. Hepatology. 2012;56:735–46.
pubmed: 22334567
doi: 10.1002/hep.25657
Manakkat Vijay GK, Kronsten VT, Bain BJ, Shawcross DL. Neutrophil vacuolation in acetaminophen-induced acute liver failure. Am J Hematol. 2015;90:461.
pubmed: 25728567
doi: 10.1002/ajh.23993
Woolbright BL, Nguyen NT, McGill MR, Sharpe MR, Curry SC, Jaeschke H. Generation of pro-and anti-inflammatory mediators after acetaminophen overdose in surviving and non-surviving patients. Toxicol Lett. 2022;367:59–66.
pubmed: 35905941
pmcid: 9849076
doi: 10.1016/j.toxlet.2022.07.813
Maes M, McGill MR, da Silva TC, Abels C, Lebofsky M, Weemhoff JL, et al. Inhibition of pannexin1 channels alleviates acetaminophen-induced hepatotoxicity. Arch Toxicol. 2017;91:2245–61.
pubmed: 27826632
doi: 10.1007/s00204-016-1885-6
Willebrords J, Maes M, Pereira IVA, da Silva TC, Govoni VM, Lopes VV, et al. Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease. Biochim Biophys Acta - Mol Basis Dis. 2018;1864:819–30.
pubmed: 29246445
doi: 10.1016/j.bbadis.2017.12.013
Vinken M. Toxic talk: pannexin1 channel communication as an emerging mechanism of toxicity. Toxicology. 2022;478: 153295.
pubmed: 35998787
doi: 10.1016/j.tox.2022.153295
Yang K, Xiao Z, He X, Weng R, Zhao X, Sun T. Mechanisms of pannexin 1 (PANX1) channel mechanosensitivity and its pathological Roles. Int J Mol Sci. 2022;23:1523.
pubmed: 35163442
pmcid: 8836264
doi: 10.3390/ijms23031523
Crespo Yanguas S, Willebrords J, Johnstone SR, Maes M, Decrock E, De Bock M, et al. Pannexin1 as mediator of inflammation and cell death. Biochim Biophys Acta - Mol Cell Res. 2017;1864:51–61.
pubmed: 27741412
doi: 10.1016/j.bbamcr.2016.10.006
Cisneros-Mejorado A, Gottlieb M, Cavaliere F, Magnus T, Koch-Nolte F, Scemes E, et al. Blockade of P2X7 receptors or pannexin-1 channels similarly attenuates postischemic damage. J Cereb Blood Flow Metab. 2015;35:843–50.
pubmed: 25605289
pmcid: 4420860
doi: 10.1038/jcbfm.2014.262
Molica F, Meens MJ, Pelli G, Hautefort A, Emre Y, Imhof BA, et al. Selective inhibition of Panx1 channels decreases hemostasis and thrombosis in vivo. Thromb Res. 2019;183:56–62.
pubmed: 31669824
doi: 10.1016/j.thromres.2019.09.028
Patil CS, Li H, Lavine NE, Shi R, Bodalia A, Siddiqui TJ, et al. ER-resident STIM1/2 couples Ca2+ entry by NMDA receptors to pannexin-1 activation. Proc Natl Acad Sci U S A. 2022;119:2112870119.
doi: 10.1073/pnas.2112870119
Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1β release by the ATP-gated P2X7 receptor. EMBO J. 2006;25:5071–82.
pubmed: 17036048
pmcid: 1630421
doi: 10.1038/sj.emboj.7601378
Lemaire M, D’Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, et al. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic nanobodies. Leukemia. 2014;28:444–7.
pubmed: 24166214
doi: 10.1038/leu.2013.292
Buelens K, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor. J Thromb Haemost. 2010;8:1302–12.
pubmed: 20180900
doi: 10.1111/j.1538-7836.2010.03816.x
Van Hout A, Klarenbeek A, Bobkov V, Doijen J, Arimont M, Zhao C, et al. CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry. Biochem Pharmacol. 2018;158:402–12.
pubmed: 30342024
doi: 10.1016/j.bcp.2018.10.015
Ye G, Gallant J, Zheng J, Massey C, Shi K, Tai W, et al. The development of nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates. Elife. 2021;10:64815.
doi: 10.7554/eLife.64815
Jensen RK, Pedersen H, Lorentzen J, Laursen NS, Vorup-Jensen T, Andersen GR. Structural insights into the function-modulating effects of nanobody binding to the integrin receptor αMβ2. J Biol Chem. 2022;298: 102168.
pubmed: 35738398
pmcid: 9287160
doi: 10.1016/j.jbc.2022.102168
Wang N, De Bock M, Decrock E, Bol M, Gadicherla A, Bultynck G, et al. Connexin targeting peptides as inhibitors of voltage- and intracellular Ca2+-triggered Cx43 hemichannel opening. Neuropharmacology. 2013;75:506–16.
pubmed: 24007825
doi: 10.1016/j.neuropharm.2013.08.021
Maes M, Crespo Yanguas S, Willebrords J, Weemhoff JL, da Silva TC, Decrock E, et al. Connexin hemichannel inhibition reduces acetaminophen-induced liver injury in mice. Toxicol Lett. 2017;278:30–7.
pubmed: 28687253
pmcid: 5800489
doi: 10.1016/j.toxlet.2017.07.007
Kanneganti TD, Lamkanfi M, Kim YG, Chen G, Park JH, Franchi L, et al. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity. 2007;26:433–43.
pubmed: 17433728
doi: 10.1016/j.immuni.2007.03.008
Albalawi F, Lu W, Beckel JM, Lim JC, McCaughey SA, Mitchell CH. The P2X7 receptor primes IL-1β and the NLRP3 inflammasome in astrocytes exposed to mechanical strain. Front Cell Neurosci. 2017;11:227.
pubmed: 28848393
pmcid: 5550720
doi: 10.3389/fncel.2017.00227
Parzych K, Zetterqvist AV, Wright WR, Kirkby NS, Mitchell JA, Paul-Clark MJ. Differential role of pannexin-1/ATP/P2X7 axis in IL-1β release by human monocytes. FASEB J. 2017;31:2439–45.
pubmed: 28246166
pmcid: 5507675
doi: 10.1096/fj.201600256
Debie P, Devoogdt N, Hernot S. Targeted nanobody-based molecular tracers for nuclear imaging and image-guided surgery. Antibodies. 2019;8:12.
pubmed: 31544818
pmcid: 6640687
doi: 10.3390/antib8010012
Woolbright BL, Jaeschke H. Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure. J Hepatol. 2017;66:836–48.
pubmed: 27913221
doi: 10.1016/j.jhep.2016.11.017
Huang G, Bao J, Shao X, Zhou W, Wu B, Ni Z, et al. Inhibiting pannexin-1 alleviates sepsis-induced acute kidney injury via decreasing NLRP3 inflammasome activation and cell apoptosis. Life Sci. 2020;254: 117791.
pubmed: 32416166
doi: 10.1016/j.lfs.2020.117791
Steen EH, Wang X, Balaji S, Butte MJ, Bollyky PL, Keswani SG. The role of the anti-inflammatory cytokine interleukin-10 in tissue fibrosis. Adv Wound Care. 2020;9:184–98.
doi: 10.1089/wound.2019.1032
Islam H, Neudorf H, Mui AL, Little JP. Interpreting ‘anti-inflammatory’ cytokine responses to exercise: focus on interleukin-10. J Physiol. 2021;599:5163–77.
pubmed: 34647335
doi: 10.1113/JP281356
Huynh L, Kusnadi A, Park SH, Murata K, Park-Min KH, Ivashkiv LB. Opposing regulation of the late phase TNF response by mTORC1-IL-10 signaling and hypoxia in human macrophages. Sci Rep. 2016;6:31959.
pubmed: 27558590
pmcid: 4997257
doi: 10.1038/srep31959
Hellenbrand DJ, Reichl KA, Travis BJ, Filipp ME, Khalil AS, Pulito DJ, et al. Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury. J Neuroinflammation. 2019;16:93.
pubmed: 31039819
pmcid: 6489327
doi: 10.1186/s12974-019-1479-3
Panchin Y, Kelmanson I, Matz M, Lukyanov K, Usman N, Lukyanov S. A ubiquitous family of putative gap junction molecules. Curr Biol. 2000;10:473–4.
doi: 10.1016/S0960-9822(00)00576-5
Penuela S, Gehi R, Laird DW. The biochemistry and function of pannexin channels. Biochim Biophys Acta - Biomembr. 2013;1828:15–22.
doi: 10.1016/j.bbamem.2012.01.017
Lutz SE, González-Fernández E, Ventura JCC, Pérez-Samartín A, Tarassishin L, Negoro H, et al. Contribution of pannexin1 to experimental autoimmune encephalomyelitis. PLoS ONE. 2013;8:66657.
doi: 10.1371/journal.pone.0066657
Velasquez S, Malik S, Lutz SE, Scemes E, Eugenin EA. Pannexin1 channels are required for chemokine-mediated migration of CD4+ T lymphocytes: role in inflammation and experimental autoimmune encephalomyelitis. J Immunol. 2016;196:4338–47.
pubmed: 27076682
doi: 10.4049/jimmunol.1502440
Mousseau M, Burma NE, Lee KY, Leduc-Pessah H, Kwok CHT, Reid AR, et al. Microglial pannexin-1 channel activation is a spinal determinant of joint pain. Sci Adv. 2018;4:9846.
doi: 10.1126/sciadv.aas9846
Cooreman A, Van Campenhout R, Ballet S, Annaert P, Van Den Bossche B, Colle I, et al. Connexin and pannexin (hemi)channels: emerging targets in the treatment of liver disease. Hepatology. 2019;69:1317–23.
pubmed: 30300925
doi: 10.1002/hep.30306
Medina CB, Chiu YH, Stremska ME, Lucas CD, Poon I, Tung KS, et al. Pannexin 1 channels facilitate communication between T cells to restrict the severity of airway inflammation. Immunity. 2021;54:1715–27.
pubmed: 34283971
pmcid: 8363584
doi: 10.1016/j.immuni.2021.06.014
Seo JH, Dalal MS, Contreras JE. Pannexin-1 channels as mediators of neuroinflammation. Int J Mol Sci. 2021;22:5189.
pubmed: 34068881
pmcid: 8156193
doi: 10.3390/ijms22105189
Willebrords J, Maes M, Crespo Yanguas S, Vinken M. Inhibitors of connexin and pannexin channels as potential therapeutics. Pharmacol Ther. 2017;180:144–60.
pubmed: 28720428
pmcid: 5802387
doi: 10.1016/j.pharmthera.2017.07.001
Jovčevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020;34:11–26.
pubmed: 31686399
doi: 10.1007/s40259-019-00392-z
Van Campenhout R, Muyldermans S, Vinken M, Devoogdt N, De Groof TWM. Therapeutic nanobodies targeting cell plasma membrane transport proteins: a high-risk/high-gain endeavor. Biomolecules. 2021;11:63.
pubmed: 33418902
pmcid: 7825061
doi: 10.3390/biom11010063
D’Huyvetter M, Vincke C, Xavier C, Aerts A, Impens N, Baatout S, et al. Targeted radionuclide therapy with a 177Lu-labeled anti-HER2 nanobody. Theranostics. 2014;4:708–20.
pubmed: 24883121
pmcid: 4038753
doi: 10.7150/thno.8156
Bao G, Tang M, Zhao J, Zhu X. Nanobody: a promising toolkit for molecular imaging and disease therapy. EJNMMI Res. 2021;11:6.
pubmed: 33464410
pmcid: 7815856
doi: 10.1186/s13550-021-00750-5
Caufriez A, Lamouroux A, Martin C, Iaculli D, Ince Ergüç E, Gozalbes R, et al. Determination of structural features that underpin the pannexin1 channel inhibitory activity of the peptide
pubmed: 37210827
doi: 10.1016/j.bioorg.2023.106612
Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. 2009;284:3273–84.
pubmed: 19010777
doi: 10.1074/jbc.M806889200
Roovers RC, Vosjan MJWD, Laeremans T, El Khoulati R, De Bruin RCG, Ferguson KM, et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer. 2011;129:2013–24.
pubmed: 21520037
pmcid: 4197845
doi: 10.1002/ijc.26145
Vugmeyster Y, Entrican CA, Joyce AP, Lawrence-Henderson RF, Leary BA, Mahoney CS, et al. Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol). Bioconjug Chem. 2012;23:1452–62.
pubmed: 22731748
doi: 10.1021/bc300066a
Bradley ME, Dombrecht B, Manini J, Willis J, Vlerick D, De Taeye S, et al. Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action. Mol Pharmacol. 2015;87:251–62.
pubmed: 25468882
doi: 10.1124/mol.114.094821
Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol. 2017;8:1603.
pubmed: 29213270
pmcid: 5702627
doi: 10.3389/fimmu.2017.01603
Beirnaert E, Desmyter A, Spinelli S, Lauwereys M, Aarden L, Dreier T, et al. Bivalent llama single-domain antibody fragments against tumor necrosis factor have picomolar potencies due to intramolecular interactions. Front Immunol. 2017;8:867.
pubmed: 28824615
pmcid: 5534440
doi: 10.3389/fimmu.2017.00867
de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, et al. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. Oncoimmunology. 2018;7:1–14.
doi: 10.1080/2162402X.2017.1375641
Khodabakhsh F, Norouzian D, Vaziri B, Ahangari Cohan R, Sardari S, Mahboudi F, et al. Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties. Artif Cells, Nanomedicine Biotechnol. 2018;46:1402–14.
doi: 10.1080/21691401.2017.1369426
Schütze K, Petry K, Hambach J, Schuster N, Fumey W, Schriewer L, et al. CD38-specific biparatopic heavy chain antibodies display potent complement-dependent cytotoxicity against multiple myeloma cells. Front Immunol. 2018;9:2553.
pubmed: 30524421
pmcid: 6262402
doi: 10.3389/fimmu.2018.02553
McGill MR, Williams CD, Xie Y, Ramachandran A, Jaeschke H. Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. Toxicol Appl Pharmacol. 2012;264:387–94.
pubmed: 22980195
pmcid: 3478469
doi: 10.1016/j.taap.2012.08.015
Kerr F, Dawson A, Whyte IM, Buckley N, Murray L, Graudins A, et al. The Australasian clinical toxicology investigators collaboration randomized trial of different loading infusion rates of N-acetylcysteine. Ann Emerg Med. 2005;45:402–8.
pubmed: 15795719
doi: 10.1016/j.annemergmed.2004.08.040
Shan S, Shen Z, Zhang C, Kou R, Xie K, Song F. Mitophagy protects against acetaminophen-induced acute liver injury in mice through inhibiting NLRP3 inflammasome activation. Biochem Pharmacol. 2019;169: 113643.
pubmed: 31542387
doi: 10.1016/j.bcp.2019.113643
Li L, Shan S, Kang K, Zhang C, Kou R, Song F. The cross-talk of NLRP3 inflammasome activation and necroptotic hepatocyte death in acetaminophen-induced mice acute liver injury. Hum Exp Toxicol. 2021;40:673–84.
pubmed: 33021112
doi: 10.1177/0960327120961158
Liu J, Jiang M, Jin Q, Wu YL, Cui ZY, Cui BW, et al. Modulation of HMGB1 release in APAP-induced liver injury: a possible strategy of chikusetsusaponin V targeting NETs formation. Front Pharmacol. 2021;12: 723881.
pubmed: 34366873
pmcid: 8333615
doi: 10.3389/fphar.2021.723881
Elshal M, Abdelmageed ME. Diacerein counteracts acetaminophen-induced hepatotoxicity in mice via targeting NLRP3/caspase-1/IL-1β and IL-4/MCP-1 signaling pathways. Arch Pharm Res. 2022;45:142–58.
pubmed: 35244883
pmcid: 8967791
doi: 10.1007/s12272-022-01373-7